Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pralsetinib Combined with Leucogen in RET Fusion-positive NSCLC
NCT07418879Not yet recruiting
- Sponsor
- Fudan University
- Start
- Feb 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
01
Overview
Open-label, single-arm trial of Leucogen in leukopenia and neutropenia, sponsored by Fudan University. Primary endpoint: Grade and incidence of leukopenia and neutropenia at 1 month. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
Leucogen
03
Conditions
leukopenianeutropenia
Beyond the preview
Go deeper on NCT07418879.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07418879.